恩扎卢胺联合镭-223治疗转移性去势抵抗性前列腺癌:EORTC 1333/PEACE-3试验结果
PEACE-3研究纳入446例转移性去势抵抗性前列腺癌(mCRPC)伴骨转移患者,随机接受恩扎卢胺单药或恩扎卢胺联合6周期镭-223治疗,主要终点为研究者评估的影像学无进展生存期(rPFS)。联合组rPFS显著改善(HR 0.69,95%CI 0.54-0.87,P=0.0009),中位rPFS为19.4个月 vs 16.4个月;中期分析总生存期(OS)HR 0.69(95%CI 0.52-0.90,P=0.0031),中位OS为42.3个月 vs 35.0个月,但因非比例风险需最终OS分析确认。
要点
- 恩扎卢胺联合镭-223较恩扎卢胺单药显著改善rPFS(HR 0.69)。
- 中期分析OS HR 0.69,但非比例风险需最终分析确认。
- 联合组≥3级不良事件发生率65.6%,常见为高血压(34%)。
核心结论
- PEACE-3研究表明,恩扎卢胺联合镭-223作为mCRPC一线治疗显著改善rPFS。
- OS在中期分析边界达到统计学显著,但研究将继续进行最终OS分析。
研究设计与样本
- EORTC 1333/PEACE-3研究为随机试验,2015年11月至2023年3月纳入446例mCRPC伴骨转移患者,其中11例接受过阿比特龙。
- 患者随机接受恩扎卢胺(无安慰剂)或恩扎卢胺联合6周期镭-223治疗;截至2018年3月,联合使用唑来膦酸或地舒单抗为强制要求。
- 主要终点为研究者评估的rPFS;关键次要终点包括OS、至后续系统性治疗时间、疼痛进展和症状性骨骼事件。
主要发现
- rPFS的HR为0.69(95%CI 0.54-0.87,P=0.0009),恩扎卢胺组中位rPFS为16.4个月(95%CI 13.8-19.2),联合组为19.4个月(95%CI 17.1-25.3)。
- 在80%OS事件时进行的预设中期分析中,OS的HR为0.69(95%CI 0.52-0.90,P=0.0031),恩扎卢胺组中位OS为35.0个月(95%CI 28.8-38.9),联合组为42.3个月(95%CI 36.8-49.1)。
- ≥3级治疗中出现的不良事件(TEAE)在恩扎卢胺组和联合组的发生率分别为55.8%和65.6%。
- 联合组最常见的≥3级TEAE为高血压(34%)、疲乏(6%)、骨折(5%)、贫血(5%)和中性粒细胞减少(5%)。
- 骨折(包括治疗中出现或治疗后、症状性或病理性、伴或不伴骨保护剂使用)在恩扎卢胺组报告30例(13.4%),联合组报告53例(24.3%)。
局限性
- 由于非比例风险,OS结果将在最终OS分析中进一步检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The EORTC 1333 'PEACE-3' study investigated the combination of enzalutamide and 6 monthly injections of radium-223 (Ra223) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. MATERIALS AND METHODS: From November 2015 to March 2023, 446 patients, including 11 who received abiraterone, were randomized to enzalutamide (without placebo) or enzalutamide combined with six cycles of Ra223. As of March 2018, the co-administration of zoledronic acid or denosumab was mandatory. The primary endpoint was radiological progression-free survival (rPFS) by investigator assessment. Key secondary endpoints included overall survival (OS), time to subsequent systemic treatment, pain progression, and symptomatic skeletal event. RESULTS: The hazard ratio (HR) for rPFS was 0.69 [95% confidence interval (CI) 0.54-0.87, P = 0.0009], with a median rPFS of 16.4 months (95% CI 13.8-19.2 months) in the enzalutamide arm and 19.4 months (95% CI 17.1-25.3 months) in the combination arm. At the preplanned interim analysis conducted at 80% of the OS events, the HR for OS was 0.69 (95% CI 0.52-0.90, P = 0.0031), with a median OS of 35.0 months (95% CI 28.8-38.9 months) in the enzalutamide arm and 42.3 months (95% CI 36.8-49.1 months) in the combination arm. Due to non-proportional hazards, this will be tested further at the final OS analysis. Treatment-emergent adverse events (TEAEs) ≥ grade 3 were recorded in 55.8% and 65.6% of the patients in the enzalutamide and combination arms, respectively. The most frequent grade ≥3 TEAEs in the combination arm were hypertension (34%), fatigue (6%), fracture (5%), anemia (5%), and neutropenia (5%). Fractures [either treatment-emergent or post-treatment, symptomatic or pathologic, or with or without bone-protecting agent (BPA) use] were reported in 30 (13.4%) patients in the enzalutamide arm and 53 patients (24.3%) in the combination arm. CONCLUSION: PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis.
引用
- Tombal B, Choudhury A, Saad F, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. Ann Oncol. 2025. PMID: 40450503. doi:10.1016/j.annonc.2025.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。